Katarina Ageborg - AstraZeneca PLC President

AZN Stock  USD 67.18  1.40  2.04%   

President

Ms. Katarina Ageborg is Executive Vice President Sustainability, Chief Compliance Officer of AstraZeneca PLC since 2011.
Tenure 13 years
Address 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
Phone44 20 3749 5000
Webhttps://www.astrazeneca.com
Katarina was appointed Executive VicePresident, Sustainability in 2017 and was a member of SET since 2011. She has overall responsibility for the delivery, design and implementation of the Company’s sustainability programme, covering three priority areas: access to healthcare; environmental protection; and ethics and transparency. She leads the Global Sustainability function, including teams focusing on Compliance, and Safety, Health and Environment. Katarina was also appointed President of AstraZeneca AB in 2018, and her role is focused on strengthening corporate reputation and relations by actively representing the company in the Swedish business and academic community. Prior to her current roles, Katarina led the Global Intellectual Property function from 2008 to 2011, during which time she streamlined the organisation and launched a new patent filing strategy before taking the role as Chief Compliance Officer

AstraZeneca PLC Management Efficiency

The company has Return on Asset of 0.085 % which means that on every $100 spent on assets, it made $0.085 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1666 %, implying that it generated $0.1666 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 11th of December 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Return On Assets are very stable compared to the past year. As of the 11th of December 2024, Asset Turnover is likely to grow to 0.79, while Total Current Assets are likely to drop about 15.3 B.
AstraZeneca PLC ADR has 28.62 B in debt with debt to equity (D/E) ratio of 0.89, which is OK given its current industry classification. AstraZeneca PLC ADR has a current ratio of 0.79, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for AstraZeneca to invest in growth at high rates of return.

Similar Executives

Showing other executives

PRESIDENT Age

Phil ThomsonGlaxoSmithKline PLC ADR
N/A
Jennifer ZacharyMerck Company
46
Anne WhiteEli Lilly and
55
James FordGlaxoSmithKline PLC ADR
N/A
Johna NortonEli Lilly and
56
Julie GerberdingMerck Company
64
Lidia FonsecaPfizer Inc
55
Fiona MarshallNovartis AG ADR
60
Hal BarronGlaxoSmithKline PLC ADR
58
Esteban SantosAmgen Inc
56
Adam DubowBristol Myers Squibb
53
JeanBaptiste ChatillonSanofi ADR
59
Dawn RogersPfizer Inc
54
Paul AutenriedBristol Myers Squibb
59
Robert DavisMerck Company
54
Kathryn WengelJohnson Johnson
58
Angela HwangPfizer Inc
58
Murdo GordonAmgen Inc
57
Brian DurkinAbbVie Inc
60
Henry GosebruchAbbVie Inc
48
Joseph WolkJohnson Johnson
54
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca Plc operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 83100 people. AstraZeneca PLC ADR (AZN) is traded on NASDAQ Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA and employs 89,900 people. AstraZeneca PLC is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

AstraZeneca PLC ADR Leadership Team

Elected by the shareholders, the AstraZeneca PLC's board of directors comprises two types of representatives: AstraZeneca PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AstraZeneca. The board's role is to monitor AstraZeneca PLC's management team and ensure that shareholders' interests are well served. AstraZeneca PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AstraZeneca PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
Marc Dunoyer, Chief Financial Officer, Executive Director
Sherilyn McCoy, Non-Executive Independent Director
Genevieve Berger, Non-Executive Independent Director
Nazneen Rahman, Non-Executive Independent Director
Jose Baselga, Executive Vice President - Research & Development Oncology
Deborah Eldracher, Non-Executive Independent Director
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer
Tony Mok, Non-Executive Independent Director
Fiona Cicconi, Executive Vice President - Human Resources
Deborah DiSanzo, Non-Executive Independent Director
Chris Sheldon, Head Relations
Leif Johansson, Non-Executive Independent Chairman of the Board
Leon Wang, Executive Vice President - International and China President
Adrian Kemp, Company Secretary
Susan MD, Executive Development
Michel Demare, Non-Executive Independent Director
Graham Chipchase, Senior Non-Executive Independent Director
Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee
Pam Cheng, Executive Vice-President of Operations and Information Technology
MBA DVM, CEO Director
Aradhana MD, CFO Director
Philip Broadley, Non-Executive Independent Director
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business
David Fredrickson, Executive Vice-President Global Head Oncology Business Unit
Jeffrey JD, Chief CHRO
Gonzalo Vina, Head Relations
Andrew Barnett, Head Relations
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals
Ruth March, Senior Oncology
Marcus Wallenberg, Non-Executive Director
Iskra Reic, Executive Vice President - Europe and Canada

AstraZeneca Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AstraZeneca PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

  0.88JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr
  0.93LLY Eli LillyPairCorr

Moving against AstraZeneca Stock

  0.87BMY Bristol Myers SquibbPairCorr
  0.84GILD Gilead SciencesPairCorr
  0.83XAIR Beyond AirPairCorr
  0.83CAH Cardinal HealthPairCorr
  0.64ESPR Esperion TherapeuticsPairCorr
The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.
The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.034
Dividend Share
2.97
Earnings Share
2.07
Revenue Per Share
2.7424
Quarterly Revenue Growth
0.18
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.